دورية أكاديمية
أعرض في EDS

Conditional survival analysis of patients with resected non-small cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Conditional survival analysis of patients with resected non-small cell lung cancer.
المؤلفون: Chaudhry T; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Krishnan V; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Donaldson AE; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Palmisano ZM; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Basu S; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Geissen NM; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Karush JM; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Alex GC; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Borgia JA; Department of Pathology, Rush University Medical Center, Chicago, Ill.; Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Ill., Liptay MJ; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill., Seder CW; Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Ill.
المصدر: JTCVS open [JTCVS Open] 2023 Sep 18; Vol. 16, pp. 948-959. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: Netherlands NLM ID: 101768541 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-2736 (Electronic) Linking ISSN: 26662736 NLM ISO Abbreviation: JTCVS Open Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam, The Netherlands] : Elsevier Ltd., [2020]-
مستخلص: Background: Conditional survival (CS) analyses provide an estimate of survival accounting for years already survived after treatment. We aim to evaluate the difference between actuarial and conditional survival in patients following lung resection for non-small cell lung cancer (NSCLC). In addition, CS analyses are used to examine whether prognosticators of survival change over time following surgery.
Methods: Patients who underwent anatomic lung resection at a single institution for pathologic stage I-IIIA NSCLC between 2010 and 2021 were identified; those who underwent wedge resection for node-negative tumors ≤2 cm were also included. CS estimates were calculated as the probability of remaining disease-free after x years of nonrecurrence (CS x ). Kaplan-Meier, log-rank, and Cox proportional hazard methods for examining CS were used for subgroup comparisons and assessing associations with baseline covariates.
Results: Overall, 863 patients met the study inclusion criteria, with a median follow-up of 44.1 months. Conditional overall survival (OS) and disease-free survival (DFS) were greater than actuarial rates at all time points after surgery. At the time of resection, male sex (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.03 to 1.72; P  = .032), tumor size >3 cm (HR, 1.17; 95% CI, 1.11-1.23; P  < .001), node positivity (HR, 3.31; 95% CI, 2.52-4.33; P  < .001), and American Joint Committee on Cancer stage ( P  < .001) were associated with DFS. However, if a patient lived 3 years without recurrence (CS 3 ), these factors were no longer prognostic of DFS.
Conclusions: Conditional survival analyses provide dynamic assessments of OS and DFS after NSCLC resection. After 3 years without recurrence, certain characteristics associated with DFS at the time of surgery no longer prognosticate recurrence.
Competing Interests: The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
(© 2023 The Author(s).)
References: J Thorac Cardiovasc Surg. 2013 Jan;145(1):75-81; discussion 81-2. (PMID: 23127371)
Front Oncol. 2021 Dec 21;11:761042. (PMID: 34993132)
Lancet. 2021 Oct 9;398(10308):1344-1357. (PMID: 34555333)
Oncol Lett. 2020 Aug;20(2):1607-1618. (PMID: 32724402)
Oncotarget. 2017 May 9;8(19):32201-32211. (PMID: 27793026)
Lung Cancer. 2009 Sep;65(3):355-62. (PMID: 19162366)
Cancer. 2009 Oct 1;115(19):4616-24. (PMID: 19569252)
JAMA Surg. 2015 Jun;150(6):538-45. (PMID: 25831462)
Cancer Res Treat. 2021 Oct;53(4):1057-1071. (PMID: 33705624)
Clin Cancer Res. 2015 Apr 1;21(7):1530-6. (PMID: 25833308)
Anticancer Res. 2012 Sep;32(9):3953-60. (PMID: 22993343)
J Biopharm Stat. 2018;28(5):927-938. (PMID: 29185865)
Chest. 1999 Sep;116(3):697-703. (PMID: 10492274)
Int J Cancer. 2021 Feb 1;148(3):626-636. (PMID: 32738818)
J Clin Oncol. 2010 May 20;28(15):2520-8. (PMID: 20406936)
J Clin Oncol. 2003 Aug 15;21(16):3035-40. (PMID: 12915592)
J Thorac Oncol. 2010 Feb;5(2):211-4. (PMID: 19901853)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Ann Thorac Surg. 2016 May;101(5):1877-82. (PMID: 26912309)
Lancet Respir Med. 2018 Dec;6(12):915-924. (PMID: 30442588)
BMC Cancer. 2012 Oct 08;12:460. (PMID: 23043308)
J Thorac Cardiovasc Surg. 2003 Jun;125(6):1300-5. (PMID: 12830048)
Chest. 2010 Sep;138(3):500-9. (PMID: 20507946)
N Engl J Med. 2020 Oct 29;383(18):1711-1723. (PMID: 32955177)
Transl Lung Cancer Res. 2014 Aug;3(4):242-9. (PMID: 25806307)
N Engl J Med. 2022 May 26;386(21):1973-1985. (PMID: 35403841)
Oncol Lett. 2019 Aug;18(2):1089-1098. (PMID: 31423169)
فهرسة مساهمة: Keywords: conditional survival; disease-free survival; non–small cell lung cancer; prognosis
تواريخ الأحداث: Date Created: 20240111 Latest Revision: 20240112
رمز التحديث: 20240112
مُعرف محوري في PubMed: PMC10775048
DOI: 10.1016/j.xjon.2023.09.010
PMID: 38204712
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-2736
DOI:10.1016/j.xjon.2023.09.010